A prime editing strategy to rewrite the γ-globin promoters and reactivate fetal hemoglobin for sickle cell disease
Open Access
- 27 November 2025
- journal article
- Published by American Society of Hematology in Blood
- Vol. 146 (22) , 2641-2655
Abstract
Fetal hemoglobin reactivation is a promising therapy for β-hemoglobinopathies. We developed a prime editing strategy that introduces multiple mutations in the fetal γ-globin promoters that are expected to increase their activity. We tested multiple targets and optimized a variety of parameters to achieve ∼50% of precise edits in a hematopoietic cell line, with minimal off-target effects. This work improved our understanding of the complex DNA repair mechanisms involved in prime editing. We tested this strategy in patients’ hematopoietic stem/progenitor cells. Although editing efficiency was variable among donors, erythroid clones carrying multiple mutations expressed a significantly higher γ-globin level than cells carrying individual mutations, confirming the potential therapeutic benefit of our combined strategy for patients with β-hemoglobinopathies.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responsesMolecular Therapy, 2024
- Phage-assisted evolution and protein engineering yield compact, efficient prime editorsCell, 2023
- Novel lentiviral vectors for gene therapy of sickle cell disease combining gene addition and gene silencing strategiesMolecular Therapy Nucleic Acids, 2023
- Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expressionNature Communications, 2022
- Harnessing DSB repair to promote efficient homology-dependent and -independent prime editingNature Communications, 2022
- Enhanced prime editing systems by manipulating cellular determinants of editing outcomesCell, 2021
- Improving cytidine and adenine base editors by expression optimization and ancestral reconstructionNature Biotechnology, 2018
- A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic conditionNature Medicine, 2016
- Editing the genome to introduce a beneficial naturally occurring mutation associated with increased fetal globinNature Communications, 2015
- GγAγ(β+) hereditary persistence of fetal hemoglobin: The Gγ – 158 C → T mutation in cis to the − 175 T → C mutation of the Aγ‐globin gene results in increased Gγ‐globin synthesisAmerican Journal of Hematology, 1993